JP2011513196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513196A5 JP2011513196A5 JP2010518498A JP2010518498A JP2011513196A5 JP 2011513196 A5 JP2011513196 A5 JP 2011513196A5 JP 2010518498 A JP2010518498 A JP 2010518498A JP 2010518498 A JP2010518498 A JP 2010518498A JP 2011513196 A5 JP2011513196 A5 JP 2011513196A5
- Authority
- JP
- Japan
- Prior art keywords
- morpholin
- compound
- dimethyl
- phenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 10
- IAAITAGXZWCRTQ-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCC1 IAAITAGXZWCRTQ-UHFFFAOYSA-N 0.000 claims 2
- JNWPEEJRMRBMPA-UHFFFAOYSA-N 2-cyclopentyl-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCC1 JNWPEEJRMRBMPA-UHFFFAOYSA-N 0.000 claims 2
- IMOFGKWQMCCNKF-UHFFFAOYSA-N 2-cyclopentyl-n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCCC1 IMOFGKWQMCCNKF-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- SCOOTUMXCXKEAD-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4,6-trimethylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(C)C=C(C)C=C1C SCOOTUMXCXKEAD-UHFFFAOYSA-N 0.000 claims 2
- BKFDFCVASNKPOA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=N1 BKFDFCVASNKPOA-UHFFFAOYSA-N 0.000 claims 2
- BPFWCATXXHFMHU-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(F)C(NC(=O)CCCCC)=C(F)C=C1N1CCOCC1 BPFWCATXXHFMHU-UHFFFAOYSA-N 0.000 claims 2
- OVEJXWFUXCATFY-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 OVEJXWFUXCATFY-UHFFFAOYSA-N 0.000 claims 2
- DKKUESYXEUWVTR-UHFFFAOYSA-N n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C=C1 DKKUESYXEUWVTR-UHFFFAOYSA-N 0.000 claims 2
- WOVDEFIGDUUBDM-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC)=C(Br)C=C1N1CCOCC1 WOVDEFIGDUUBDM-UHFFFAOYSA-N 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95330807P | 2007-08-01 | 2007-08-01 | |
| DKPA200701110 | 2007-08-01 | ||
| PCT/DK2008/050191 WO2009015667A1 (en) | 2007-08-01 | 2008-07-31 | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513196A JP2011513196A (ja) | 2011-04-28 |
| JP2011513196A5 true JP2011513196A5 (enExample) | 2011-07-21 |
Family
ID=39810209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518498A Ceased JP2011513196A (ja) | 2007-08-01 | 2008-07-31 | ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100256145A1 (enExample) |
| EP (1) | EP2185149A1 (enExample) |
| JP (1) | JP2011513196A (enExample) |
| KR (1) | KR20100050502A (enExample) |
| CN (1) | CN101790374A (enExample) |
| AR (1) | AR070513A1 (enExample) |
| AU (1) | AU2008281112A1 (enExample) |
| BR (1) | BRPI0814180A2 (enExample) |
| CA (1) | CA2694887A1 (enExample) |
| CL (1) | CL2008002273A1 (enExample) |
| EA (1) | EA201070189A1 (enExample) |
| MX (1) | MX2010001171A (enExample) |
| NZ (1) | NZ582942A (enExample) |
| TW (1) | TW200920350A (enExample) |
| UA (1) | UA97847C2 (enExample) |
| WO (1) | WO2009015667A1 (enExample) |
| ZA (1) | ZA201000129B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| US20110059980A1 (en) * | 2008-02-21 | 2011-03-10 | Yasuaki Oobayashi | Solid preparation for oral administration |
| NZ590852A (en) | 2008-07-16 | 2013-03-28 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands trans-1{ 4-[2-[4-(2,3-dichlorophenyl)-piperizin-1-yl]-ethyl]-cyclohexyl} -3,3-dimethyl-urea also known as cariprazine |
| HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
| WO2010105189A1 (en) * | 2009-03-12 | 2010-09-16 | The Johns Hopkins University | Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age |
| WO2010105960A1 (en) | 2009-03-17 | 2010-09-23 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
| DE102009013612A1 (de) * | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung |
| TW201041857A (en) * | 2009-05-11 | 2010-12-01 | Lundbeck & Co As H | Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide |
| MX2011012743A (es) * | 2009-05-29 | 2012-04-20 | Astellas Pharma Inc | Nueva composicion farmaceutica para la prevencion y/0 tratamiento del trastorno por deficit de atencion/hiperactividad. |
| WO2011133661A2 (en) | 2010-04-21 | 2011-10-27 | Research Development Foundation | Methods and compositions related to dopaminergic neuronal cells |
| EP2590961A1 (en) | 2010-07-08 | 2013-05-15 | Pfizer Inc | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP2844247A4 (en) * | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| CN103508960B (zh) * | 2012-06-29 | 2017-12-12 | 江苏先声药业有限公司 | 苯并杂环衍生物 |
| CN103508943B (zh) * | 2012-06-29 | 2017-06-09 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
| CN103012381B (zh) * | 2013-01-10 | 2015-01-07 | 山东大学 | 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用 |
| KR102331833B1 (ko) | 2013-12-02 | 2021-11-25 | 케모센트릭스, 인크. | Ccr6 화합물 |
| KR20170076673A (ko) * | 2014-10-24 | 2017-07-04 | 오노 야꾸힝 고교 가부시키가이샤 | Kcnq2∼5 채널 활성화제 |
| US10526280B2 (en) | 2014-11-13 | 2020-01-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | (2-amino-4-(arylamino)phenyl carbamates |
| KR20190008411A (ko) | 2016-06-10 | 2019-01-23 | 사이플루어 라이프 사이언시즈, 인크 | 플로오르화 2-아미노-4-(치환된 아미노)페닐 카르밤산염 유도체 |
| EP3468962A1 (en) | 2016-06-13 | 2019-04-17 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| EP3366683A1 (en) * | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
| EP4424364A3 (en) | 2017-03-28 | 2024-11-27 | Gilead Sciences, Inc. | Methods of treating liver disease |
| US10590067B2 (en) | 2018-02-20 | 2020-03-17 | H. Lundbeck A/S | Alcohol derivatives of carboxamides as Kv7 potassium channel openers |
| PL3755684T3 (pl) | 2018-02-20 | 2023-11-06 | H. Lundbeck A/S | Pochodne alkoholowe jako substancje otwierające kanał potasowy kv7 |
| TWI788325B (zh) * | 2018-02-21 | 2023-01-01 | 丹麥商Ｈ 朗德貝克公司 | 作為Ｋｖ７鉀通道開放劑的醇衍生物 |
| US11358930B2 (en) | 2018-04-20 | 2022-06-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Selective potassium channel agonists |
| CN110511220B (zh) * | 2018-05-22 | 2022-04-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用 |
| CN108707087B (zh) | 2018-06-29 | 2020-10-16 | 河北医科大学 | 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途 |
| CN108863893A (zh) * | 2018-07-09 | 2018-11-23 | 湖南博隽生物医药有限公司 | 二氢吲哚类衍生物及其在药物中的应用 |
| AU2020209564B2 (en) | 2019-01-15 | 2022-12-01 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| CN118388474A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| ES3034153T3 (en) | 2019-08-02 | 2025-08-13 | H Lundbeck As | Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures |
| SMT202400445T1 (it) | 2019-08-02 | 2024-11-15 | H Lundbeck As | Derivati alcolici come attivatori dei canali del potassio kv7 |
| AR119521A1 (es) | 2019-08-02 | 2021-12-22 | H Lundbeck As | DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7 |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| KR20220098746A (ko) | 2019-11-08 | 2022-07-12 | 제논 파마슈티칼스 인크. | 우울 장애 치료 방법 |
| KR102643653B1 (ko) * | 2020-11-13 | 2024-03-06 | 기초과학연구원 | 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물 |
| IL304920A (en) * | 2021-02-09 | 2023-10-01 | Xenon Pharmaceuticals Inc | A voltage-gated potassium channel opener for use in the treatment of anhedonia |
| CN116535353A (zh) * | 2022-01-25 | 2023-08-04 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的酰胺类化合物及其制备和应用 |
| WO2024099269A1 (zh) * | 2022-11-11 | 2024-05-16 | 华东师范大学 | 芳基酰胺化合物、包含其的药物组合物及其用途 |
| WO2025038930A1 (en) * | 2023-08-17 | 2025-02-20 | Xenon Pharmaceuticals, Inc. | Azepane and pyrrolidine compounds and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN172468B (enExample) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
| US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
| GB9915414D0 (en) * | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Medical use |
| US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
| WO2001010380A2 (en) * | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Benzanilides as potassium channel openers |
| US6469042B1 (en) * | 2001-02-20 | 2002-10-22 | Bristol-Myers Squibb Company | Fluoro oxindole derivatives as modulators if KCNQ potassium channels |
| US6855829B2 (en) * | 2001-02-20 | 2005-02-15 | Bristol-Myers Squibb Company | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease |
| US6831080B2 (en) * | 2001-05-31 | 2004-12-14 | Bristol-Myers Squibb Company | Cinnamide derivatives as KCNQ potassium channel modulators |
| EP1581516A4 (en) * | 2002-11-22 | 2007-10-17 | Bristol Myers Squibb Co | BENZYLAMIDE 3-HETEROCYCLIC DERIVATIVES AS POTASIC CHANNEL OPENING AGENTS |
| US6933308B2 (en) * | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
| EP1578740B1 (en) * | 2002-12-27 | 2007-03-21 | H. Lundbeck A/S | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system |
| EP1603858A2 (en) * | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
| AU2004220424B2 (en) * | 2003-03-14 | 2009-01-22 | H. Lundbeck A/S | Substituted aniline derivatives |
| AU2004222626B2 (en) * | 2003-03-21 | 2010-06-24 | H. Lundbeck A/S | Substituted p-diaminobenzene derivatives |
| WO2004096767A1 (en) * | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
| TWI357901B (en) * | 2004-03-12 | 2012-02-11 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivati |
| UA89503C2 (uk) * | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
| WO2006092143A1 (en) * | 2005-03-03 | 2006-09-08 | H. Lundbeck A/S | Substituted pyridine derivatives |
| AU2006322461A1 (en) * | 2005-09-09 | 2007-06-14 | H. Lundbeck A/S | Pyrimidine derivatives and their use as KCNQ potassium channels openers |
| KR20080096659A (ko) * | 2006-02-07 | 2008-10-31 | 하. 룬트벡 아크티에 셀스카브 | 정신분열증 증상의 치료 또는 감소를 위한 ｋｃｎｑ개방제의 용도 |
| WO2007128462A1 (en) * | 2006-05-02 | 2007-11-15 | Chris Rundfeldt | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
-
2008
- 2008-07-31 UA UAA201000852A patent/UA97847C2/ru unknown
- 2008-07-31 CA CA2694887A patent/CA2694887A1/en not_active Abandoned
- 2008-07-31 WO PCT/DK2008/050191 patent/WO2009015667A1/en not_active Ceased
- 2008-07-31 CN CN200880101135A patent/CN101790374A/zh active Pending
- 2008-07-31 JP JP2010518498A patent/JP2011513196A/ja not_active Ceased
- 2008-07-31 EP EP08773327A patent/EP2185149A1/en not_active Withdrawn
- 2008-07-31 EA EA201070189A patent/EA201070189A1/ru unknown
- 2008-07-31 MX MX2010001171A patent/MX2010001171A/es not_active Application Discontinuation
- 2008-07-31 NZ NZ582942A patent/NZ582942A/en not_active IP Right Cessation
- 2008-07-31 AR ARP080103329A patent/AR070513A1/es not_active Application Discontinuation
- 2008-07-31 AU AU2008281112A patent/AU2008281112A1/en not_active Abandoned
- 2008-07-31 BR BRPI0814180-0A2A patent/BRPI0814180A2/pt not_active IP Right Cessation
- 2008-07-31 KR KR1020107002904A patent/KR20100050502A/ko not_active Withdrawn
- 2008-07-31 US US12/671,505 patent/US20100256145A1/en not_active Abandoned
- 2008-08-01 CL CL2008002273A patent/CL2008002273A1/es unknown
- 2008-08-01 TW TW097129164A patent/TW200920350A/zh unknown
-
2010
- 2010-01-07 ZA ZA2010/00129A patent/ZA201000129B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513196A5 (enExample) | ||
| UA97847C2 (ru) | Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии | |
| JP2010526777A5 (enExample) | ||
| JP2009538276A5 (enExample) | ||
| JP2010517990A5 (enExample) | ||
| JP2011524850A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| JP2007277267A5 (enExample) | ||
| JP2010513478A5 (enExample) | ||
| JP2010527365A5 (enExample) | ||
| JP2006526031A5 (enExample) | ||
| JP2010095546A5 (enExample) | ||
| JP2007016035A5 (enExample) | ||
| JP2015518055A5 (enExample) | ||
| JP2005533104A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| JP2010511631A5 (enExample) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2012509263A5 (enExample) | ||
| JP2015511632A5 (enExample) | ||
| JP2008513510A5 (enExample) | ||
| JP2008546770A5 (enExample) | ||
| JP2009503045A5 (enExample) | ||
| JP2012501334A5 (enExample) |